To evaluate the potential risk of ADE resulting from ZIKV-IG administration, eighty Ifnar1-/- mice (8 to 10 weeks old, 40 males and 40 females) were divided into four different treatment groups (10 males and 10 females per group) and treated with ZIKV-IG, Gamunex® (hyperimmune control), 4G2 (positive control) or Isotype mAb (negative control) 24 ± 4 hours prior to infection (Table 3). Here, IFNAR1 is linked to acute disseminated encephalomyelitis.